Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY5 | O95622 | 6/20 | 0.47 |
| ▸ | ADK | P55263 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 10/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7156161 | 1.00 | ADCY5 (0.47) | ADCY5ADKPRMT5WDR77NR1I2 | |
| SCHEMBL7114896 | 1.00 | ADCY5 (0.47) | ADCY5ADKPRMT5WDR77NR1I2 | |
| SCHEMBL7114998 | 0.85 | PRMT5 (0.38) | ADCY5PRMT5WDR77NR1I2ALB | |
| SCHEMBL30969131 | 0.78 | ADCY5 (0.74) | ADCY5NR1I2ALBPDE4D | |
| SCHEMBL111590 | 0.78 | ADCY5 (0.74) | ADCY5NR1I2ALBPDE4D | |
| SCHEMBL12157255 | 0.78 | ADCY5 (0.74) | ADCY5NR1I2ALBPDE4D | |
| SCHEMBL5997273 | 0.78 | ADCY5 (0.74) | ADCY5NR1I2ALBPDE4D | |
| SCHEMBL5998483 | 0.78 | ADCY5 (0.74) | ADCY5NR1I2ALBPDE4D | |
| SCHEMBL5997270 | 0.78 | ADCY5 (0.74) | ADCY5NR1I2ALBPDE4D | |
| SCHEMBL23584600 | 0.74 | ADCY5 (0.47) | ADCY5ADKPRMT5WDR77METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045508-A1 | (1r,cis)-4-(4-amino-7h-pyrrolo'2,3-i(d) pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045508-A1 | (1r,cis)-4-(4-amino-7h-pyrrolo'2,3-i(d) pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral | MAVS, ZC3HAV1, SARS1 | ADCY5 4573/4885ADK 1956/4885PRMT5 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.